| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
369.19(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
30,300 |
| Total Buy Value |
$0 |
$0 |
$863 |
$132,633 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simon Nicholas J III |
10% Owner |
– – • |
2010-11-03 |
4 |
OE |
$2.54 |
$6,171,682 |
I/I |
2,428,171 |
5,917,614 |
|
- |
|
| Healthcare Partners Vii, L.p. |
10% Owner |
– – • |
2010-11-03 |
4 |
OE |
$2.54 |
$2,378,558 |
I/I |
935,814 |
4,253,057 |
|
- |
|
| Richman Eric I |
President and Interim CEO |
• • – |
2010-06-17 |
4 |
B |
$1.58 |
$15,767 |
D/D |
10,000 |
70,573 |
2.81 |
- |
|
| Pappajohn John |
Director |
– • – |
2010-05-27 |
4 |
B |
$1.51 |
$68,936 |
D/D |
45,656 |
911,164 |
2.39 |
- |
|
| Pappajohn John |
Director |
– • – |
2010-05-26 |
4 |
B |
$1.49 |
$80,869 |
D/D |
54,344 |
865,508 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2010-05-18 |
4 |
B |
$1.50 |
$124,721 |
D/D |
83,253 |
841,164 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2010-05-17 |
4 |
B |
$1.42 |
$23,791 |
D/D |
16,747 |
757,911 |
2.39 |
- |
|
| Richman Eric I |
See Remarks |
• • – |
2010-03-23 |
4 |
D |
$3.40 |
$35,700 |
D/D |
(10,500) |
99,322 |
|
- |
|
| Fusco Joan |
Senior VP, Operations |
• – – |
2010-03-05 |
4 |
D |
$1.80 |
$3,150 |
D/D |
(1,750) |
36,730 |
|
- |
|
| Cook Francesca M |
VP, Policy & GVMNT Affairs |
• – – |
2010-01-21 |
4 |
D |
$1.73 |
$4,453 |
D/D |
(2,574) |
43,264 |
|
- |
|
| Fusco Joan |
SVP, Operations |
• – – |
2010-01-21 |
4 |
D |
$1.73 |
$4,034 |
D/D |
(2,332) |
38,480 |
|
- |
|
| Camut Christopher C |
VP, Govt Contracts |
• – – |
2010-01-21 |
4 |
D |
$1.73 |
$4,379 |
D/D |
(2,531) |
46,777 |
|
- |
|
| Riddle Valerie D |
VP, Medical Director |
• – – |
2010-01-21 |
4 |
D |
$1.73 |
$4,759 |
D/D |
(2,751) |
56,073 |
|
- |
|
| Morges Wayne |
VP, Regulatory Affairs & Qual |
• – – |
2010-01-21 |
4 |
D |
$1.73 |
$4,427 |
D/D |
(2,559) |
35,532 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2009-12-11 |
4 |
B |
$1.20 |
$60,000 |
D/D |
50,000 |
741,164 |
2.39 |
- |
|
| Pappajohn John |
Director |
– • – |
2009-12-11 |
4 |
B |
$1.19 |
$118,930 |
D/D |
100,000 |
811,164 |
2.39 |
- |
|
| Wright David P |
President and CEO |
• • – |
2009-12-11 |
4 |
B |
$1.16 |
$28,940 |
D/D |
25,000 |
399,500 |
2.81 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2009-03-26 |
4 |
S |
$0.00 |
$2 |
D/D |
(17,735) |
591,164 |
|
- |
|
| Pappajohn John |
Director |
– • – |
2009-03-26 |
4 |
S |
$0.00 |
$2 |
D/D |
(17,735) |
711,164 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2009-03-12 |
4 |
S |
$0.00 |
$21 |
D/D |
(212,814) |
608,899 |
|
- |
|
| Pappajohn John |
Director |
– • – |
2009-03-12 |
4 |
S |
$0.00 |
$21 |
D/D |
(212,814) |
728,899 |
|
- |
|
| Wright David P |
President & CEO |
• • – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
37,185 |
374,500 |
|
- |
|
| Karp Jordan P |
Senior VP, General Counsel |
• – – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
4,792 |
|
- |
|
| Camut Christopher C |
VP, Chief Financial Officer |
• – – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
25,308 |
49,308 |
|
- |
|
| Richman Eric I |
SVP, Business Development |
• – – |
2009-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
30,573 |
60,573 |
|
- |
|
417 Records found
|
|
Page 13 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.49 (6.98%) 
